Despite current injecting drug users (IDUs) being the major risk group for new hepatitis C virus (HCV) infections in most countries, they constitute a small minority of study populations in almost all studies of acute HCV infection treatment. The Australian Trial in Acute Hepatitis C (ATAHC) is examining natural history and treatment efficacy among predominantly IDU-acquired acute HCV. Recruitment is through an Australian network of primary and tertiary care sites. Eligible participants are offered treatment with pegylated-interferon alpha-2a (PEG-IFN) for 24 weeks, with both treated and untreated participants followed for up to three years. Quantitative and qualitative data on injecting behaviour is collected on study participants. Partici...
Background: Screening and treatment of hepatitis C virus (HCV) infection in people who use drugs (PW...
Despite recent improvements in outcomes of treatment for infection with hepatitis C virus (HCV), ver...
Background: Among people who inject drugs (PWID), the prevalence of hepatitis C virus (HCV) infectio...
Background: A barrier to hepatitis C virus (HCV) treatment among people who inject drugs (PWID) has ...
The majority of new and existing cases of hepatitis C virus (HCV) infection occur among people who i...
© 2016 Society for the Study of Addiction. Aims: To estimate adherence and response to therapy for c...
Aims: To estimate adherence and response to therapy for chronic hepatitis C virus (HCV) infection am...
Injection drug use accounts for the majority of incident and prevalent cases of hepatitis C virus (H...
Gaps in hepatitis C virus (HCV) testing, diagnosis, liver disease assessment and treatment uptake am...
Although injection drug users represent the majority of incident and prevalent cases of hepatitis C,...
Background: The advent of novel, highly efficacious, and well tolerated hepatitis C virus (HCV) ther...
Background: Hepatitis C virus (HCV)-related morbidity and mortality are rising. Despite recent thera...
Background: Access to hepatitis C virus (HCV) treatment remains extremely limited among people who i...
Background. Access to hepatitis C virus (HCV) treatment remains extremely limited among people who i...
Despite increases in treatment uptake for hepatitis C viral infection (HCV) in Australia since the i...
Background: Screening and treatment of hepatitis C virus (HCV) infection in people who use drugs (PW...
Despite recent improvements in outcomes of treatment for infection with hepatitis C virus (HCV), ver...
Background: Among people who inject drugs (PWID), the prevalence of hepatitis C virus (HCV) infectio...
Background: A barrier to hepatitis C virus (HCV) treatment among people who inject drugs (PWID) has ...
The majority of new and existing cases of hepatitis C virus (HCV) infection occur among people who i...
© 2016 Society for the Study of Addiction. Aims: To estimate adherence and response to therapy for c...
Aims: To estimate adherence and response to therapy for chronic hepatitis C virus (HCV) infection am...
Injection drug use accounts for the majority of incident and prevalent cases of hepatitis C virus (H...
Gaps in hepatitis C virus (HCV) testing, diagnosis, liver disease assessment and treatment uptake am...
Although injection drug users represent the majority of incident and prevalent cases of hepatitis C,...
Background: The advent of novel, highly efficacious, and well tolerated hepatitis C virus (HCV) ther...
Background: Hepatitis C virus (HCV)-related morbidity and mortality are rising. Despite recent thera...
Background: Access to hepatitis C virus (HCV) treatment remains extremely limited among people who i...
Background. Access to hepatitis C virus (HCV) treatment remains extremely limited among people who i...
Despite increases in treatment uptake for hepatitis C viral infection (HCV) in Australia since the i...
Background: Screening and treatment of hepatitis C virus (HCV) infection in people who use drugs (PW...
Despite recent improvements in outcomes of treatment for infection with hepatitis C virus (HCV), ver...
Background: Among people who inject drugs (PWID), the prevalence of hepatitis C virus (HCV) infectio...